MedTrace Logo

PET Imaging of Subjects Using 124I-PU-AD

NCT03371420 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-04-18

No results posted yet for this study

Summary

This is a first in-human, open-label pilot (microdose) study of the positron-emitting agent 124I-PU-AD in subjects with specific cancer types (solid malignancy, lymphoma, and/or myeloma) and/or Alzheimer's disease.

Conditions

Interventions

DRUG

PU-AD

DEVICE

PET Scan

OTHER

Blood Draws

Sponsors & Collaborators

  • Memorial Sloan Kettering Cancer Center

    collaborator OTHER

  • Weill Medical College of Cornell University

    collaborator OTHER

  • Rockefeller University

    collaborator OTHER

  • Samus Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Morgan, MS, JD · Sponsor GmbH

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2019-06-10
Completion
2019-06-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03371420 on ClinicalTrials.gov